Axe Compute sells Helomics lab to DataMeds AI, completes neocloud GPU transition

Axe Compute Inc.

Sold Helomics to DataMeds AI for 636,328 DataMeds shares (19.99% stake) plus $1,363,672 convertible note at $1.00/share.
Closing occurred Sept 11, 2026; shares and note are restricted securities with a 12-month lock-up period.
Sale completes Axe Compute's shift to pure-play GPU-as-a-Service; Helomics was last unit from Predictive Oncology era.
Company will pay remaining base rent on two Pittsburgh Helomics leases through their current terms.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.